iTonic Holdings Ltd. (ITOC)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 1 | 1 | 1 | 0 | 1 | 1 | - |
| Operating profit | $m | -5 | -5 | ||||||
| Net profit | $m | - | 0 | 0 | -0 | -1 | -5 | -5 | - |
| EPS reported | $ | -0.32 | -0.32 | ||||||
| Operating cashflow per share | $ | -0.20 | -0.19 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.20 | -0.19 | ||||||
| Free cash flow | $m | -3 | -3 | ||||||
| Net debt | $m | -3 | -3 | ||||||
| Book value equity | $m | 6 | 6 | ||||||
| Book value per share | $ | 0.38 | 0.36 | ||||||
| Number of shares | m | 16.04 | 16.8 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.10 | 1.10 | ||||||
| P/S LTM | x | 12.91 | 12.91 | ||||||
| P/FCF LTM | x | -2.08 | -2.08 | ||||||
| EV/EBITDA LTM | x | -1.04 | -1.05 | ||||||
| EV/Sales LTM | x | 10.33 | 3.04 | ||||||
| Earnings Yield LTM | % | -75.50% | -96.83% | ||||||
| FCF Yield | % | -48.05% | -48.05% | ||||||
| Quality | |||||||||
| ROE | % | -83.26% | -93.93% | ||||||
| ROIC | % | -59.10% | -59.10% | ||||||
| Operating margin | % | -9.92% | -9.92% | ||||||
| Gross margin | % | +62.59% | +62.59% | ||||||
| FCF/Sales | % | -620.26% | -620.26% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +16.70% | +16.70% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -22.69 | -22.69 | ||||||
| Net Debt/EBITDA | x | 0.26 | 0.26 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +2.12% | +4.86% | ||||||
| Net debt/Equity | x | -0.45 | -0.45 | ||||||
| Gross debt/equity | x | 0.02 | 0.02 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
iTonic Holdings Ltd., a healthcare solutions firm, specializes in the development and commercialization of software and devices for brachytherapy. Its advanced proprietary treatment planning system centers on radioactive particle implantation, a form of radiotherapy employed in cancer treatment to precisely position radioactive sources within patients, thereby eradicating malignant cells and reducing tumor size. Key among its offerings is FTTPS, a sophisticated treatment planning system engineered for diverse malignant tumors. This system excels at defining the target volume, determining the prescribed dose, establishing safety margins for organs at risk, and formulating a precise dose distribution plan essential for brachytherapy patients. Founded in Beijing, China, in 1998, the company operated as Pheton Holdings Ltd. until its rebranding to iTonic Holdings Ltd. in January 2026. iTonic Holdings Ltd. functions as a subsidiary of ZJW (BVI) LTD.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
iTonic Holdings Ltd., a healthcare solutions firm, specializes in the development and commercialization of software and devices for brachytherapy. Its advanced proprietary treatment planning system centers on radioactive particle implantation, a form of radiotherapy employed in cancer treatment to precisely position radioactive sources within patients, thereby eradicating malignant cells and reducing tumor size. Key among its offerings is FTTPS, a sophisticated treatment planning system engineered for diverse malignant tumors. This system excels at defining the target volume, determining the prescribed dose, establishing safety margins for organs at risk, and formulating a precise dose distribution plan essential for brachytherapy patients. Founded in Beijing, China, in 1998, the company operated as Pheton Holdings Ltd. until its rebranding to iTonic Holdings Ltd. in January 2026. iTonic Holdings Ltd. functions as a subsidiary of ZJW (BVI) LTD.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free